CHARACTERISTICS OF CHILDREN WITH ANTI-NMDAR ENCEPHALITIS TREATED WITH THERAPEUTIC PLASMA EXCHANGE
Main Article Content
Abstract
Objective: to describe characteristics of children diagnosed with Anti-NMDAR encephalitis who were treated with therapeutic plasma exchange (TPE). Method: a retrospective case series, conducted on patients diagnosed with Anti-NMDAR encephalitis underwent TPE treatment at Children's Hospital No. 2, between January 2019 and June 2022. Results: a total of 32 patients were enrolled in the study, 18 in the Anti-NMDAR encephalitis group and 14 in the probable antibody-negative autoimmune encephalitis group. The Anti-NMDAR encephalitis group had a male to female ratio of 1:2.6 and a median age of 7 (4.5-12.3) years old. The median duration from onset to hospital admission was 8.5 (4-14) days. The majority (89.9%) of the Anti-NMDAR encephalitis group had severe encephalitis with symptoms including altered consciousness (100%), psychosis (94.4%), speech impairment (94.4%), seizure (83.3%), and movement disorders (100%). The Anti-NMDAR group also showed a higher frequency of delusions, hyperactivity, and dyskinesias compared to the probable antibody-negative autoimmune encephalitis group. In terms of laboratory evaluation, 83.3% of Anti-NMDAR encephalitis cases showed abnormal cerebrospinal fluid (CSF) results, with a higher white blood cell count and rate of leukocytosis compared to the other group. EEG showed abnormalities in 75% of cases and brain MRI results showed abnormalities in 33.3% of cases. In terms of treatment, 5.6% received TPE monotherapy, 83.3% received IVMT+TPE, and 11.1% received IVMT+TPE+ IVIG. 77.8% of cases showed improvement after treatment, with a median length of hospital stay of 39 days. Conclusions: severe Anti-NMDAR encephalitis patients typically showed symptoms of altered consciousness, neuropsychiatric, language deficits, and dyskinetic movements. Severe cases of Anti-NMDAR encephalitis had a higher rate of treatment response, and the combination of IVMT + TPE was effective in improving patient outcomes.
Article Details
Keywords
Anti-NMDAR encephalitis, autoimmune encephalitis, therapeutic plasma exchange
References
2. Jafarpour S, Santoro J D (2022). Autoimmune Encephalitis. Pediatr Rev. 43 (4), p. 198-211.
3. Nosadini M, Thomas T, Eyre M, et al. (2021). International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 8 (5).
4. Pham H. P, Daniel-Johnson J A, Stotler B A, et al. (2011). Therapeutic plasma exchange for the treatment of anti-NMDA receptor encephalitis. J Clin Apher. 26 (6), p. 320-5.
5. Sai Yang, Zhang X, Feng M, et al. (2018). Clinical diagnosis and treatment of pediatric anti-N-methyl-D-aspartate receptor encephalitis: A single center retrospective study. Exp Ther Med. 16 (2), p. 1442-1448.
6. Suppiej A, Nosadini M, Zuliani L, et al. (2016). Plasma exchange in pediatric anti-NMDAR encephalitis: A systematic review. Brain Dev. 38 (7), p. 613-22.
7. Wickramasinghe N, Dasanayake D, Malavige N, et al. (2021). Autoimmune encephalitis in a South Asian population. BMC Neurol. 21 (1), p. 203.
8. Zhang Y, Huang H. J, Chen W. B, et al. (2021). Clinical efficacy of plasma exchange in patients with autoimmune encephalitis. Ann Clin Transl Neurol. 8 (4), p. 763-773.